Arecor: New Global Partner Signed & Clinical Trial Update

Cambridge, UK., 3rd May 2019: Arecor, today announces that it has signed a collaboration with a new major global pharmaceutical partner. Under the collaboration, Arecor will leverage its ArestatTM technology to develop superior liquid formulations of its partner’s proprietary products. The partner will fund the development work and has the option to acquire the rights to the formulation and associated Intellectual Property under a technology licensing model. This partnership further demonstrates the value of Arecor’s ArestatTM technology platform in delivering superior therapeutic treatments that are otherwise not achievable.

Sarah Howell, Chief Executive Officer at Arecor, said: “This new partnership with a major pharmaceutical company further strengthens our pipeline of commercial projects within our formulation technology business. Our commercial relationships with pharmaceutical partners represent the opportunity to showcase both our technology and scientific expertise. With the option to grant an exclusive licence to the formulation developed, we potentially have an ongoing role to support our pharmaceutical partner in the development of their superior therapeutic products.”


7th May 2019: Arecor today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.

Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels. This is to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypo and hyperglycaemia.

The double-blind, randomised, three-way cross over Phase I clinical study will compare the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial is being conducted in
Austria at an internationally recognised centre of excellence in the field of diabetes research and preliminary results are expected towards the end of the year.

Sarah Howell, Chief Executive Officer at Arecor, said: “The initiation of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes. I look forward to reporting on the progress of this product candidate, the first in our proprietary product development pipeline.”